COVID-19 Vaccine Update: Serum Institute Joins Bill Gates Foundation to Produce 100 Million Doses in India, Other Nations at a Price Less Than Rs 250

Earlier this week, the Drugs Controller General of India (DCGI) approved Serum Institute's permission to conduct clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine in India.

By India.com News Desk | Published:Fri, August 07, 2020 5:41pm

COVID-19 Vaccine Latest News: The Serum Institute of India (SII) on Friday said that it is set to enter a partnership of $150 million with the Bill & Melinda Gates Foundation-backed GAVI to manufacture 100 million doses of COVID-19 vaccine for India and other emerging economies. Also Read - COVID-19: Stroke Patients With Coronavirus Have High Inflammation, Death Rate, Warn Researchers

The Pune-based research firm has already been authorised for conducting Phase II+III of human trial rounds for the development and commercialisation of two leading vaccine candidates in the world - Oxford University and AstraZeneca's Covishield, and Novavax - in India and other low and middle-income countries. Also Read - Brucellosis Outbreak: This Is Why India Needs to Take Precautions Right Away

"The funding will support at-risk manufacturing by SII for candidate vaccines from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO prequalification," the Serum Insitute said in a statement. Also Read - Sputnik V: Trials For Russian Coronavirus Vaccine May Begin in India in Upcoming Weeks

Together, GAVI and SII, intend to lead COVAX, a scheme designed for the fast and equitable access of coronavirus vaccine around the globe, and deliver 2 billion doses of the COVID-19 vaccine by the end of 2021.

The institute is planning to introduce candidate vaccines from AstraZeneca and Novavax for COVID-19 at less than Rs 250 per dose in India, and it is expected to be available as early as the first half of 2021.

Earlier this week, the Drugs Controller General of India (DCGI) approved Serum Institute's permission to conduct clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine in India.

The experimental vaccine is already in the midst of Phase II and III clinical trials in the UK, Phase III trials in Brazil, and Phase I and II clinical trials in South Africa.

Published:Fri, August 07, 2020 5:41pm

Tags

coronavirus COVID-19 vaccine Pune Serum Institute of India vaccine

India News

Chief Minister Yogi Adityanath Meets Bollywood Personalities Over Film City in Uttar Pradesh's Noida
Provide Food & Monetary Support Urgently to Starving 1.2 Lakh Sex Workers: SC Directs States
Sonia Gandhi Returns With Son Rahul From US Post Health Check-up Amid Ongoing Monsoon Session
Maharashtra: Death Toll Rises to 22 in Bhiwandi Building Collapse, Two Adjacent Towers Vacated
Over 1 Crore Migrant Workers Walked Back to Their Home States During March-June: Govt Tells Parliament

Latest News

LIVE Rajasthan Royals vs Chennai Super Kings Match 4 Live Cricket Score And Updates: Chawla Gets Uthappa, Smith Reaches Fifty
KKR vs MI Dream11 Team Hints And Predictions, Captain And Vice-Captain, Fantasy Cricket IPL 2020: Kolkata Knight Riders vs Mumbai Indians, Match 5 Sheikh Zayed Stadium, Abu Dhabi at 7:30 PM IST Wednesday September 23
IPL 2020: Picking Right Playing XI A Challenge For Kolkata Knight Riders, Says Captain Dinesh Karthik
Face Shields Inefficacious Against Coronavirus: Japanese Supercomputer Fugaku
IPL 2020: KKR's Eoin Morgan Says Wickets in UAE Have Been Similar to English Conditions

Explore more